Literature DB >> 11039581

Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family.

I B Ginjaar1, A L Kneppers, J D v d Meulen, L V Anderson, M Bremmer-Bout, J C van Deutekom, J Weegenaar, J T den Dunnen, E Bakker.   

Abstract

Within one X-linked muscular dystrophy family, different phenotypes for three males occurred: (1) a severely affected Becker patient with cardiomyopathy, (2) a mildly affected Becker patient, and (3) an apparently healthy male with elevated serum CK levels. In the muscle biopsy specimen of patient2 one out of four antibodies (NCL-DYS1) showed absence of dystrophin. The protein truncation test detected a truncated dystrophin for both muscle tissue and lymphocytes of this patient next to an additional near normal size fragment in muscle. Genomic sequence analysis revealed a nonsense mutation in exon 29 (4148C > T) of the dystrophin gene. Sequence analysis of the mRNA fragment of the larger peptide showed skipping of exon 29, restoring an open reading frame. Consequently, the epitope of the antibody NCL-DYS1 is mapped to exon 29. The variable clinical features of the three relatives from healthy to severely affected therefore seems to be related to the level of skipping of exon 29. This finding underscores the future potential of gene therapeutic strategies aimed at inducing exon skipping in Duchenne muscular dystrophy, to generate a much milder disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039581     DOI: 10.1038/sj.ejhg.5200535

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

1.  Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.

Authors:  Van Khanh Tran; Yasuhiro Takeshima; Zhujun Zhang; Mariko Yagi; Atsushi Nishiyama; Yasuaki Habara; Masafumi Matsuo
Journal:  J Med Genet       Date:  2006-05-31       Impact factor: 6.318

2.  One hundred twenty-one dystrophin point mutations detected from stored DNA samples by combinatorial denaturing high-performance liquid chromatography.

Authors:  Annalaura Torella; Amelia Trimarco; Francesca Del Vecchio Blanco; Anna Cuomo; Stefania Aurino; Giulio Piluso; Carlo Minetti; Luisa Politano; Vincenzo Nigro
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

3.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

4.  A 'nonsense' mutation leads to aberrant splicing of hMLH1 in a German hereditary non-polyposis colorectal cancer family.

Authors:  J Baehring; C Sutter; M Kadmon; M V Knebel Doeberitz; J Gebert
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 5.  Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.

Authors:  Eric P Hoffman; Abby Bronson; Arthur A Levin; Shin'ichi Takeda; Toshifumi Yokota; Andreas R Baudy; Edward M Connor
Journal:  Am J Pathol       Date:  2011-05-23       Impact factor: 4.307

6.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

Review 7.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 8.  Normal and altered pre-mRNA processing in the DMD gene.

Authors:  Sylvie Tuffery-Giraud; Julie Miro; Michel Koenig; Mireille Claustres
Journal:  Hum Genet       Date:  2017-06-09       Impact factor: 4.132

Review 9.  Modifying muscular dystrophy through transforming growth factor-β.

Authors:  Ermelinda Ceco; Elizabeth M McNally
Journal:  FEBS J       Date:  2013-04-24       Impact factor: 5.542

Review 10.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.